Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02418624
Other study ID # M14REV
Secondary ID NL50610.031.1420
Status Completed
Phase Phase 1
First received
Last updated
Start date May 2015
Est. completion date January 2019

Study information

Verified date January 2019
Source The Netherlands Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase I trial to determine the recommended phase two dose of the combination of carboplatin and olaparib.


Description:

A 3+3 dose escalation trial of 2 cycles (21 days) carboplatin and olaparib combination therapy, followed by olaparib monotherapy until progression or unacceptable toxicity in patients with advanced cancer.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date January 2019
Est. primary completion date January 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria:

1. Histological or cytological proof of advanced cancer pre-treated with maximally one line of systemic chemotherapy in the advanced setting and any line of hormonal therapy for advanced disease, and potentially benefitting from olaparib-carboplatin combination therapy (prior (neo-)adjuvant chemotherapy is accepted and does not count as one line, since administered in early stage disease);

2. Age = 18 years;

3. Able and willing to give written informed consent;

4. WHO performance status of 0, 1 or 2;

5. Able and willing to undergo blood sampling for PK and PD analysis;

6. Life expectancy = 3 months, allowing adequate follow up of toxicity evaluation and antitumor activity;

7. Evaluable disease according to RECIST 1.1 criteria;

8. Minimal acceptable safety laboratory values

1. ANC of = 1.5 x 10^9 /L

2. Hemoglobin of at least 6.2 mM and no transfusions in the last 28 days.

3. Platelet count of = 100 x 10^9 /L

4. Hepatic function as defined by serum bilirubin = 1.5 x ULN (or < 3 x ULN in case of known Gilbert syndrome), ASAT and ALAT 2.5 x ULN (or <5 x ULN in case of liver metastasis)

5. Renal function as defined by serum creatinine =1.5 x ULN or creatinine clearance = 50 mL/min (by Cockcroft-Gault formula);

9. Negative pregnancy test (urine/serum) for female patients with childbearing potential;

Exclusion criteria

1. Any treatment with investigational drugs within 28 days prior to receiving the first dose of investigational treatment; or 21 days for standard (neo-)adjuvant chemotherapy, hormonal and immunotherapy;

2. Patients who have received high dose alkylating agents, a PARP1 inhibitor or carboplatin pretreatment; unless no progression on carboplatin had been observed during earlier treatment and the last carboplatin administration had been longer than 6 months ago;

3. Any current treatment with drugs that induce or inhibit the CYP3A4 system : http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteracti onslabeling/ucm093664.htm#inVivo or APPENDIX IX

4. Women who have a positive pregnancy test (urine/serum) and/or who are breast feeding;

5. Unreliable contraceptive methods. Women and men enrolled in this trial must agree to use a reliable contraceptive method throughout the study (adequate contraceptive methods are: oral, injected or implanted hormonal methods, intra-uterine devices or systems, condom or other barrier contraceptive measures, sterilization and true abstinence)

6. Radiotherapy within the last four weeks prior to receiving the first dose of investigational treatment; except 1x8 Gy for pain palliation then a seven days interval should be maintained;

7. Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients;

8. Patients with known active hepatitis B or C;

9. Recent myocardial infarction (< six months) or unstable angina;

10. Symptomatic brain metastases. If adequately treated with resection and/or irradiation and patients are at least four weeks completely free of symptoms of these metastases and without medication related to these metastases patients could be eligible if all other in- and exclusion criteria are obeyed.

11. Known leptomeningeal metastases.

12. Patients with myelodysplastic syndrome or acute myeloid leukemia

13. Any medical condition not yet specified above that is considered to possibly, probably or definitely interfere with study procedures, including adequate follow-up and compliance and/or would jeopardize safe treatment.

Study Design


Intervention

Drug:
carboplatin, olaparib
2 cycles of carboplatin and olaparib combination therapy followed by olaparib monotherapy.

Locations

Country Name City State
Netherlands Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Amsterdam

Sponsors (1)

Lead Sponsor Collaborator
The Netherlands Cancer Institute

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose The dose level at which more than 1/6 patients develop a dose limiting toxicity per doselevel of 3 to 6 patients (when 3-6 patients have completed DLT period of 3 weeks)
Secondary Pharmacokinetics (area under time-concentration curve (AUC)) Pharmacokinetics (PK) measurements of olaparib alone and olaparib in combination with carboplatin 1 year
Secondary Pharmacodynamics (PAR (Poly(ADP) ribose) activation measured with the PAR assay) PAR (Poly(ADP) ribose) activation measured with the PAR assay 1 year
Secondary Objective Response Rate Objective Response Rate according to Response Evaluation Criteria in Solid Tumors (RECIST) 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2